FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.